Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

An FDA advisory panel is pushing for a framework to use pathogen-agnostic sequencing (PAS) as a frontline tool for detecting emerging infectious disease outbreaks. Unlike traditional tests, PAS scans genetic material without needing to know the pathogen in advance — making it a powerful early-warning system. The panel says the technology is ready, but broader adoption will require investment, better validation standards, and safeguards to minimize false results.
The FDA's Microbiology Devices Panel is championing a new approach to outbreak detection — one that doesn't require scientists to know what they're looking for. At a November 19 general issues meeting, the panel recommended building a formal framework for pathogen-agnostic sequencing (PAS), a method that analyzes all genetic material in a patient sample without targeting a specific pathogen. Panel acting chair Dr. Robin Patel called it a potential game-changer for early outbreak identification, noting the technology is now widely distributed and available in the field.
But it's not without hurdles. FDA officials flagged concerns around false positives/negatives, long turnaround times, complex results, and cost — particularly for resource-strapped public health labs. A real-world example from Massachusetts illustrated the stakes: during a September 2026 enterovirus uptick with unusual neurological symptoms, PAS wasn't used due to resource and validation gaps, leaving clinicians without critical strain data.
Key Takeaways:
Why it matters: As new and unexpected pathogens continue to emerge, having a diagnostic tool that doesn't depend on pre-existing knowledge of a threat could be the difference between early containment and a full-blown outbreak.